Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    TopAbstracts in Schizophrenia 06/26/2008 - (DGNews)
    TopAbstracts in Schizophrenia 06/12/2008 - (DGNews)
    TopAbstracts in Schizophrenia 05/29/2008 - (DGNews)
    Antipsychotics Found to Have Different Ethnic and Metabolic Profiles: Presented at APA - (DGDispatch)
    TopAbstracts in Schizophrenia 05/15/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
  • Multimodal Management Emphasized in Early-Onset Schizophrenia
  • Improving Functional Outcomes: Assessment and Management of Cognitive Dysfunction in Patients with Schizophrenia

    Webcasts/CME archive

     Recent cases - Schizophrenia
      Diabetic Control and Atypical Antipsychotics: A Case Report
      A Familial Concurrence of Schizophrenia and Gaucher's Disease
      Necrotising Colitis Related to Clozapine? A Rare but Life Threatening Side Effect
      Case Report: Psychosis in an Adolescent with Sickle Cell Disease
      Case Report: Rapidly Fatal Bowel Ischaemia on Clozapine Treatment

      Cases archive
        




      my personal edition > schizophrenia > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Aripiprazole Versus Placebo in the Treatment of Chronic Schizophrenia: Presented at APA

      By Bruce Sylvester

      PHILADELPHIA, PA -- May 23, 2002 -- The investigative drug aripiprazole provides effective and safe antipsychotic treatment in patients with chronic schizophrenia, researchers reported here this week at the annual meeting of the American Psychiatric Association (APA).

      "The most important implication of this study is that it shows that aripiprazole is effective in significantly reducing the time-to-relapse as well as the rate of relapse in patients with schizophrenia who are being treated with medication," said lead investigator Teresa Pigott, MD, director of clinical trials in the department of psychiatry at the University of Florida School of Medicine in Gainesville, Florida.

      The purpose of the study was to assess the time to relapse with aripiprazole, compared to placebo, over 26 weeks in stable patients with chronic schizophrenia.

      The multicenter, randomized, double-blind, placebo-controlled study enrolled 310 subjects with chronic schizophrenia who were evaluated as stable, with no significant improvement or worsening in the previous three months and baseline on the Positive and Negative Symptoms for Schizophrenia (PANSS) scale of 82. They were randomized to aripiprazole 15 mg/day or placebo. Efficacy was determined by time to relapse, PANSS Total Score, and Clinical Global Improvement (CGI) score.

      Significantly fewer patients in the aripiprazole group (34 percent) relapsed by study end point compared to placebo (57 percent). Aripiprazole also increased the time to relapse by two fold.

      The agent was well tolerated , with an adverse events rate comparable to placebo, the researchers found. No significant changes occurred in Simpson-Angus Scale (SAS), Involuntary Movement Scale (AIMS), and Barnes Akathisia scores in either group. Weight gain in the aripiprazole group was comparable to placebo, Dr. Pigott said.



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send